<< Back to News

System Formulary Update
HIV Entry, Fusion, and Attachment Inhibitors

Situation

The HIV Entry, Fusion, and Attachment Inhibitors class review and formulary standardization was approved at the April 2021 System Pharmacy and Therapeutics Committee meeting.

Background

The following medications were reviewed: efuvirtide, maraviroc, fostemsavir, and ibalizumab-uiyk

Assessment/Recommendations

Changes Effective: Tuesday July 27, 2021

System P&T voted to include the following products on the UNC Health System Drug Formulary:

• Ibalizumab-uiyk (Trogarzo): 200 mg/1.33 mL vial
  • Restricted the outpatient or clinic encounters (ie, no inpatient use)

As a result, the following products will be removed from the inpatient drug formulary:

• Maraviroc tablet: 150 mg, 300 mg